DechraŽ Pharmaceuticals PLC (LSE symbol DPH) Releases its 2017 Half-yearly Financial Report

Monday, February 27, 2017 Drug News J E 4

LONDON, February 27, 2017 /PRNewswire/ --

Ian Page, Chief Executive Officer: "Our core portfolio continues to grow, the enhanced product pipeline is delivering new products and good progress has been made on the rationalisation and integration of our recent acquisitions."


The Group has performed strongly throughout the first six months of the financial year ending 30 June 2017 (the Period). This result has been driven by a solid revenue performance in our core businesses, good market penetration from recently launched pipeline products and a strong performance from our recent acquisitions. The operating profit performance has been enhanced by the successful rationalisation and integration of these acquisitions, prudent cost control in our core businesses and a significant favourable foreign exchange tail wind.

2017 HY Highlights 

-  Total Group revenue of Ł172.6 million, a growth of 34.7% at Constant Exchange Rate (CER) (55.9% at Actual Exchange Rate (AER)).

-  Core (excluding acquisitions) European Pharmaceuticals (EU Pharmaceuticals) Segment revenue growth of 5.9% at CER (20.0% at AER).

-  Core North American Pharmaceuticals (NA Pharmaceuticals) Segment revenue growth of 10.2% at CER (31.7% at AER).

-  Sales growth across all product groups; Companion Animal Products (CAP), Food producing Animal Products (FAP), Equine and Diets.

-  Strong performance from recently acquired businesses, exceeding our expectations.

-  Underlying operating profit increased by 28.6% at CER (47.1% at AER).

-  Net cash inflow from underlying operating activities of Ł43.9 million with a cash conversion of 124.0%.  

Financial Summary 

                                        Six months     Six months   Growth at   Growth at
                                        ended          ended        actual      constant 
                                        31.12.16       31.12.15     exchange    exchange
                                        GBPm           GBPm         rate        rate
    Revenue                              172.6          110.7       55.9%       34.7%

    Gross profit                          92.2           63.5       45.2%      27.2%
    Gross profit %                       53.4%          57.4%
    Operating profit                      38.6            26.3       47.1%     28.6%
    EBITDA                                41.6           28.7       45.0%      27.7%
    Diluted EPS                         31.25p         21.99p       42.1%      24.5%
    Gross profit                          88.2           62.5       41.2%      24.0%
    Gross profit %                       51.1%          56.4%
    Operating profit                      17.6           15.9       10.7%
    Diluted EPS                          13.65p        12.74p        7.1%


The Group continues to perform well with current trading meeting management expectations. Our core portfolio continues to grow, the enhanced product pipeline is delivering new products and good progress has been made on the rationalisation and integration of our recent acquisitions. The Board therefore remains confident in our strategy, our future prospects and our expectations for full year performance.

To read the 2017 Half Yearly Report in full please visit

Or at


All growth rates for both underlying and reported financial results included in the Dechra report are at CER, unless otherwise stated. This shows the year on year growth rates as if exchange rates had remained the same as in the previous year. The Group presents a number of non-GAAP Alternative Performance Measures (APM's). This allows investors to understand better the underlying performance of the Group, by excluding amortisation of acquired intangibles and impairment (if any) of acquired intangibles, acquisition expenses, fair value of uplift of inventory acquired through business combinations, rationalisation costs, loss on extinguishment of debt, and fair value and other movements on deferred and contingent consideration. EBITDA is defined as underlying earnings before interest, tax, depreciation and amortisation.

SOURCE Dechra Pharmaceuticals PLC



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Animals in Experimental Research in Europe are Tre...
SecureAppbox - the first GDPR cloud administration...